

References – Xigris

1. Bernard G *et al.* Efficacy and safety of recombinant human activated Protein C for severe sepsis, PROWESS study group. *N Engl J Med* 2001; 344(10):699-709
2. Wheeler AP and Bernard GR. Current concepts: Treating patients with severe sepsis. *NEJM* 1999;340(3):207-214
3. Vervloet MG *et al.* Derangements of coagulation and fibrinolysis in critically ill patient with sepsis and septic shock. *Seminars in thrombosis and homeostasis* 1998;24(1):33-44
4. Glauser MP Pathophysiologic basis of sepsis: Considerations for future strategies of intervention. *Crit Care Med* 2000;28(9):S4-S8
5. Hugo ten Cate. Pathophysiology of disseminated intravascular coagulation in sepsis. *Crit Care Med* 2000;28(9):S9-S11
6. Levi M. Sepsis and the coagulation system. *Advances in Sepsis* 2000;(1):16-22
7. Somogyi-Zalud E *et al.* Dying with acute respiratory failure or multiple organ system failure with sepsis. *J AM Geriatr Soc* 2000;48:S140-S145
8. Levi M *et al.* Pathogenesis of Disseminated intravascular coagulation in sepsis. *JAMA* 1993;70(8):975-979
9. Mayers I and Johnson D. Septic Shock: treating more than just blood pressure. *CMAJ* 2000;162(3):369-370
10. Bone RC *et al.* Sepsis: A new hypothesis for pathogenesis of the disease process. *Chest* 1997;12(1):235-243
11. Bone RC *et al.* Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. *Chest* 1992;101(6):1644-1655
12. Russell J. *et al.* Changing pattern of organ dysfunction in early human sepsis is related to mortality. *Crit Care Med* 2000;28(10):3405-3411
13. FDA briefing document: anti-infective advisory committee drotrecogin alfa (activated)
14. Gordon R. *et al.* Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. *Crit Care Med* 2001;29(11):2051-2059
15. Baumgartner JD. Calandra T. Treatment of sepsis, pasts and future avenues. *Drugs* 1999;57(2):127-132
16. Kanji S. *et al.* Recombinant Human Activated Protein C, drotrecogin alfa (activated): A novel therapy for severe sepsis. *Pharmacotherapy* 2001;21(11):1389-1402
17. Product Monograph of Xigris